EnvarsusXR

Phase 3Small molecule

AAlbert Einstein Healthcare Network

EnvarsusXR is one of 44 small molecule programs targeting Liver Transplant. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver TransplantActive, not recruiting

Liver TransplantPhase 3

Active, not recruiting

Competition

Competitive Landscape

96 competitors in Liver Transplant

#DrugCompanyPhaseTrials

Giapreza

LLa Jolla Pharmaceutical Company

Phase 3

1 2

Darbepoetin

Bayer

Phase 3

1 3

Prothrombin Complex Concentrate

CSL Behring

Phase 3

1 4

Rezzayo

MMundipharma (China) Pharmaceutical Co. Ltd

Phase 3

1 5

EnvarsusXR

AAlbert Einstein Healthcare Network

Phase 3

1 6

Lenvima

Eisai

Preclinical

2 7

Octreotide

Johnson & Johnson

Preclinical

2 8

Beyfortus

BeiGene

Preclinical

1 9

Prostigmin

Merck & Co.

Preclinical

1 10

Myfortic

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Liver Transplant1 trial

Evaluate the Clinical Benefits of EnvarsusXR in Post Liver Transplant

Active, not recruiting·AAlbert Einstein Healthcare Network·Phase 2/3·NCT03386305·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for EnvarsusXR. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EnvarsusXR compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EnvarsusXR. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Albert Einstein Healthcare Network company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAlbert Einstein Healthcare Network

EnvarsusXR

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Liver Transplant1 trial

References

Drug Info

Quick Facts

Related News